Skip to main content
Erschienen in: Journal of Radiation Oncology 4/2017

27.07.2017 | Original Research

Active monitoring in non-invasive breast cancer: insight gained from a large national database

verfasst von: Daniel M. Trifiletti, Surbhi Grover, Bertram W. Maidment III, Timothy N. Showalter, Shayna L. Showalter

Erschienen in: Journal of Radiation Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The objective was to evaluate women diagnosed with ductal carcinoma in situ (DCIS) preoperatively and elucidate factors, including time from biopsy to excision, associated with invasive disease found on final pathology (underestimation).

Methods

The National Cancer Database was queried for women with preoperative DCIS receiving lumpectomy/mastectomy from 1998 to 2012 and investigated for factors associated with underestimation (invasive disease in the breast/nodes on excision).

Results

One hundred fifty-six thousand five hundred thirty-five women met inclusion criteria and 10.8% had underestimation of disease. 9.1% had invasive disease in the breast alone, 0.4% had nodal disease despite only DCIS in the breast, and 1.4% had both invasive disease in the breast and the axillary nodes. The adjusted risk of underestimation of invasive disease increased steadily with more time from biopsy to surgery (p < 0.001), as did the adjusted risk nodal disease (p < 0.001).

Conclusions

Several presurgical findings can predict for occult-invasive breast cancer including time from diagnosis to definitive surgery.
Literatur
1.
Zurück zum Zitat Ryerson AB, Eheman CR, Altekruse SF, et al (2016) Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer Ryerson AB, Eheman CR, Altekruse SF, et al (2016) Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer
2.
Zurück zum Zitat Harding C, Pompei F, Burmistrov D et al (2015) Breast cancer screening, incidence, and mortality across US counties. JAMA Intern Med 175:1483–1489CrossRefPubMed Harding C, Pompei F, Burmistrov D et al (2015) Breast cancer screening, incidence, and mortality across US counties. JAMA Intern Med 175:1483–1489CrossRefPubMed
3.
Zurück zum Zitat Esserman LJ, Thompson IM, Reid B et al (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:e234–e242CrossRefPubMedPubMedCentral Esserman LJ, Thompson IM, Reid B et al (2014) Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:e234–e242CrossRefPubMedPubMedCentral
5.
7.
Zurück zum Zitat Ryser MD, Worni M, Turner EL et al (2016) Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst 108:djv372CrossRefPubMed Ryser MD, Worni M, Turner EL et al (2016) Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst 108:djv372CrossRefPubMed
8.
Zurück zum Zitat Brennan ME, Turner RM, Ciatto S et al (2011) Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 260:119–128CrossRefPubMed Brennan ME, Turner RM, Ciatto S et al (2011) Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 260:119–128CrossRefPubMed
11.
Zurück zum Zitat Yen TW, Hunt KK, Ross MI et al (2005) Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200:516–526CrossRefPubMed Yen TW, Hunt KK, Ross MI et al (2005) Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200:516–526CrossRefPubMed
12.
Zurück zum Zitat Dillon MF, McDermott EW, Quinn CM et al (2006) Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only. J Surg Oncol 93:559–563CrossRefPubMed Dillon MF, McDermott EW, Quinn CM et al (2006) Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only. J Surg Oncol 93:559–563CrossRefPubMed
13.
Zurück zum Zitat Goyal A, Douglas-Jones A, Monypenny I et al (2006) Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat 98:311–314CrossRefPubMed Goyal A, Douglas-Jones A, Monypenny I et al (2006) Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat 98:311–314CrossRefPubMed
14.
Zurück zum Zitat Maffuz A, Barroso-Bravo S, Najera I et al (2006) Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ. J Exp Clin Cancer Res 25:223–227PubMed Maffuz A, Barroso-Bravo S, Najera I et al (2006) Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ. J Exp Clin Cancer Res 25:223–227PubMed
15.
Zurück zum Zitat Meijnen P, Oldenburg HS, Loo CE et al (2007) Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg 94:952–956CrossRefPubMed Meijnen P, Oldenburg HS, Loo CE et al (2007) Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg 94:952–956CrossRefPubMed
16.
Zurück zum Zitat Moran CJ, Kell MR, Flanagan FL et al (2007) Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg 194:172–175CrossRefPubMed Moran CJ, Kell MR, Flanagan FL et al (2007) Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg 194:172–175CrossRefPubMed
17.
Zurück zum Zitat Rutstein LA, Johnson RR, Poller WR et al (2007) Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ. Breast J 13:251–257CrossRefPubMed Rutstein LA, Johnson RR, Poller WR et al (2007) Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ. Breast J 13:251–257CrossRefPubMed
18.
Zurück zum Zitat Dominguez FJ, Golshan M, Black DM et al (2008) Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 15:268–273CrossRefPubMed Dominguez FJ, Golshan M, Black DM et al (2008) Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 15:268–273CrossRefPubMed
19.
Zurück zum Zitat Schneider C, Trocha S, McKinley B et al (2010) The use of sentinel lymph node biopsy in ductal carcinoma in situ. Am Surg 76:943–946PubMed Schneider C, Trocha S, McKinley B et al (2010) The use of sentinel lymph node biopsy in ductal carcinoma in situ. Am Surg 76:943–946PubMed
20.
Zurück zum Zitat Han JS, Molberg KH, Sarode V (2011) Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J 17:223–229CrossRefPubMed Han JS, Molberg KH, Sarode V (2011) Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J 17:223–229CrossRefPubMed
21.
Zurück zum Zitat Sanders ME, Schuyler PA, Dupont WD et al (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103:2481–2484CrossRefPubMed Sanders ME, Schuyler PA, Dupont WD et al (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103:2481–2484CrossRefPubMed
22.
Zurück zum Zitat Francis A, Fallowfield L, Rea D (2015) The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol 27:6–8CrossRef Francis A, Fallowfield L, Rea D (2015) The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol 27:6–8CrossRef
23.
Zurück zum Zitat Francis A, Thomas J, Fallowfield L et al (2015) Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 51:2296–2303CrossRefPubMed Francis A, Thomas J, Fallowfield L et al (2015) Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 51:2296–2303CrossRefPubMed
24.
Zurück zum Zitat Pilewskie M, Olcese C, Patil S et al (2016) Women with low-risk DCIS eligible for the LORIS trial after complete surgical excision: how low is their risk after standard therapy? Ann Surg Oncol 23:4253–4261CrossRefPubMed Pilewskie M, Olcese C, Patil S et al (2016) Women with low-risk DCIS eligible for the LORIS trial after complete surgical excision: how low is their risk after standard therapy? Ann Surg Oncol 23:4253–4261CrossRefPubMed
25.
Zurück zum Zitat Alvarado M, Carter DL, Guenther JM et al (2015) The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS score result. J Surg Oncol 111:935–940CrossRefPubMed Alvarado M, Carter DL, Guenther JM et al (2015) The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS score result. J Surg Oncol 111:935–940CrossRefPubMed
26.
Zurück zum Zitat Rakovitch E, Nofech-Mozes S, Hanna W et al (2015) A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152:389–398CrossRefPubMedPubMedCentral Rakovitch E, Nofech-Mozes S, Hanna W et al (2015) A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152:389–398CrossRefPubMedPubMedCentral
Metadaten
Titel
Active monitoring in non-invasive breast cancer: insight gained from a large national database
verfasst von
Daniel M. Trifiletti
Surbhi Grover
Bertram W. Maidment III
Timothy N. Showalter
Shayna L. Showalter
Publikationsdatum
27.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 4/2017
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-017-0322-7

Weitere Artikel der Ausgabe 4/2017

Journal of Radiation Oncology 4/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.